2026-01-04 - Analysis Report
## Natera Inc. (NTRA) Stock Analysis

**Natera Inc. (NTRA) Overview:** Natera is a genetic testing company focused on non-invasive prenatal testing (NIPT) and cancer screening.

**1. Return Rate Comparison:**

*   **NTRA Cumulative Return:** 126.28%
*   **VOO (S&P 500) Cumulative Return:** 91.00%
*   **Divergence:** 36.28
*   **Relative Divergence:** 47.9

**Analysis:** NTRA has outperformed the S&P 500 significantly over the analyzed period, with a cumulative return difference of 36.28%. The relative divergence of 47.9 indicates that the current divergence is positioned slightly below the median within its historical range, suggesting that the outperformance isn't at its peak historically.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha    | Beta     | Cap(B) |
|------------|----------|----------|----------|----------|--------|
| 2016-2018  | 16.0%    | 56.0%    | 13.0%    | 1.5      | 1.9    |
| 2017-2019  | 49.0%    | 58.5%    | 32.0%    | 1.7      | 4.7    |
| 2018-2020  | 177.0%   | 58.5%    | 156.0%   | 1.3      | 13.9   |
| 2019-2021  | 89.0%    | 33.9%    | 46.0%    | 1.4      | 13.0   |
| 2020-2022  | -74.0%   | 76.8%    | -72.0%   | 1.4      | 5.6    |
| 2021-2023  | -183.0%  | 76.8%    | -184.0%  | 1.6      | 8.7    |
| 2022-2024  | 11.0%    | 60.6%    | -9.0%    | 1.5      | 22.1   |
| 2023-2025  | 158.0%   | 39.0%    | 95.0%    | 1.3      | 31.9   |

**Analysis:**

*   **Alpha:** NTRA's alpha values fluctuate significantly, indicating periods of both substantial outperformance and underperformance relative to its beta-adjusted benchmark. The alpha is highly variable and is linked to the rapid growth and market sentiment changes around the firm's products.
*   **Beta:** NTRA has a beta consistently above 1, indicating higher volatility than the market. The Beta value has remained quite stable.
*   **CAGR:** Fluctuating CAGR values show periods of rapid growth (e.g., 2018-2020, 2023-2025) and significant declines (e.g., 2021-2023).
*   **MDD:** The Maximum Drawdown (MDD) indicates high risk with substantial potential losses, with drawdowns exceeding 50% in several periods.

**2. Recent Stock Price Fluctuations:**

*   **Current Price:** 228.84
*   **Previous Close:** 229.09
*   **Change:** -0.11
*   **5-day SMA:** 230.59
*   **20-day SMA:** 232.743
*   **60-day SMA:** 212.5072

**Analysis:** The current price is slightly below the 5-day and 20-day Simple Moving Averages (SMA), suggesting a potential short-term downward trend. However, it's significantly above the 60-day SMA, indicating an overall upward trend in the medium term. The small price change from the previous close suggests relative price stability recently.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 45.74 (Neutral - neither overbought nor oversold)
*   **PPO:** -0.7265 (Slightly below zero, indicating a potential weakening of the upward trend)
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -1.8 (단기하락 - Short-term decline)
*   **Expected Return (%):** -44.5 (Expected underperformance compared to S&P 500 if invested long-term)

**Analysis:**

*   The MRI suggests a medium investment recommendation.
*   The RSI is neutral, suggesting the stock is neither overbought nor oversold.
*   The negative PPO could indicate a loss of momentum in the recent uptrend.
*   The hybrid signal suggest a buy recommendation with no cash on hand.
*   The negative expected return indicates that, despite outperformance in the past, future performance might be weaker than the S&P 500.
*   The recent relative divergence change indicates a short-term decline.

**4. Recent News & Significant Events:**

*   **Zacks Research Upgrade:** Suggests positive sentiment from at least one analyst firm.
*   **Druckenmiller's Investment:** A notable investor taking a significant position can be a positive sign.
*   **Valuation Assessment After Surge:** Indicates that the stock has experienced substantial price appreciation, prompting a valuation review.
*   **Barclays Price Target Raise:** Suggests optimism from Barclays, with a target significantly above the current price.
*   **Medical Stock Nearing Buy Point:** Indicates the stock is showing bullish technical patterns according to *Investor's Business Daily*.
*   **Responsive Playbooks and NTRA Inflection:** Suggests a turning point or strategic change within the company.

**Analysis:** Recent news is predominantly positive, with analyst upgrades, a notable investor taking a large position, and bullish technical indications. However, the valuation assessment after a surge suggests caution, implying that the stock might be considered expensive by some.

**4-2. Analyst Opinions:**

*   **Consensus:** Strong Buy
*   **Mean:** 1.47 (~Strong Buy)
*   **Opinions:** 19
*   **Target Price (avg/high/low):** 248.37 / 285.00 / 186.00

**Analysis:** The analyst consensus is strongly bullish, with a mean rating close to "Strong Buy" and a significant number of opinions contributing to the consensus. The average target price is above the current price, suggesting upside potential.

**5. Recent Earnings Analysis:**

| 날짜       | EPS      | 매출        |
|------------|----------|-------------|
| 2025-11-07 | -0.64   | 0.59 B$    |
| 2025-08-08 | -0.74   | 0.55 B$    |
| 2025-05-09 | -0.5    | 0.50 B$    |
| 2024-11-12 | -0.26   | 0.44 B$    |
| 2025-11-07 | -0.26   | 0.44 B$    |

**Analysis:** Natera has consistently reported negative EPS (Earnings Per Share), indicating a lack of profitability. However, revenue is steadily increasing, suggesting growth in the company's core business. The most recent EPS is -0.64 on revenue of $0.59B, showing that losses have improved in that last period reported.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $0.59B     | 64.91%        |
| 2025-06-30   | $0.55B     | 63.41%        |
| 2025-03-31   | $0.50B     | 63.12%        |
| 2024-12-31   | $0.48B     | 62.94%        |
| 2024-09-30   | $0.44B     | 61.79%        |

**Analysis:** Revenue is showing consistent growth. The profit margin is relatively stable and strong, indicating that the core business is efficient. The revenue figures match those found in the earnings report.

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-09-30   | $1.25B     | -6.99%   |
| 2025-06-30   | $1.25B     | -8.10%   |
| 2025-03-31   | $1.24B     | -5.40%   |
| 2024-12-31   | $1.20B     | -4.50%   |
| 2024-09-30   | $0.88B     | -3.60%   |

**Analysis:** Equity is increasing over time, reflecting positive capital growth. However, the Return on Equity (ROE) is negative, confirming the lack of profitability.

**7. Comprehensive Analysis:**

Natera (NTRA) has significantly outperformed the S&P 500, however, the financial data indicates that the company is not yet profitable and has a negative expected return compared to S&P 500 if invested long-term. The company is generating increasing revenue and maintaining a stable profit margin, but negative EPS and ROE highlight ongoing profitability challenges. Analyst ratings are very positive, and recent news events are largely supportive, suggesting confidence in the company's future potential. The high beta and maximum drawdown figures point to significant volatility and risk. The recent pullback from the 5/20 day SMA is a short-term factor that indicates caution should be taken.

**In Summary:** While NTRA has exhibited strong growth and positive analyst sentiment, its lack of profitability and high volatility suggest that it is a higher-risk investment. Investors should carefully consider their risk tolerance and conduct further due diligence before investing in NTRA.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.